KMT2A and central nervous system cancer: Inhibition of the epigenetic regulators SVIL and MLL1, either genetically [short hairpin RNA (shRNA)] or pharmacologically (MLL1 inhibitor), reduced YTHDF2 expression and suppressed oncogenic transformation of LFS astrocytes and p53-mutant glioma.